Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 3/20 | 0.80 |
| ▸ | MAOB | P27338 | 8/20 | 0.80 |
| ▸ | MAOA | P21397 | 1/20 | 0.68 |
| ▸ | MAPT | P10636 | 1/20 | 0.67 |
| ▸ | BCHE | P06276 | 5/20 | 0.66 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.65 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.65 |
| ▸ | ACHE | P22303 | 3/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10497493 | 0.96 | ABCG2 (0.74) | ABCG2MAOBMAOAMAPTBCHE | |
| SCHEMBL10497417 | 0.96 | ABCG2 (0.74) | ABCG2MAOBMAOAMAPTBCHE | |
| SCHEMBL23788887 | 0.92 | ABCG2 (0.84) | ABCG2MAOBBCHECYP1A1CYP1B1 | |
| SCHEMBL29014210 | 0.89 | MAOB (0.71) | ABCG2MAOBMAOAMAPTBCHE | |
| SCHEMBL29014271 | 0.89 | MAOB (0.71) | ABCG2MAOBMAOAMAPTBCHE | |
| SCHEMBL29181783 | 0.89 | MAOB (0.71) | ABCG2MAOBMAOAMAPTBCHE | |
| SCHEMBL25218115 | 0.89 | ABCG2 (1.00) | ABCG2MAOBMAPTBCHECYP1A1 | |
| SCHEMBL25265255 | 0.89 | ABCG2 (1.00) | ABCG2MAOBMAPTBCHECYP1A1 | |
| SCHEMBL25195480 | 0.89 | ABCG2 (1.00) | ABCG2MAOBMAPTBCHECYP1A1 | |
| SCHEMBL10497614 | 0.89 | MAOB (1.00) | ABCG2MAOBMAOAMAPTCYP1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9974778-B2 | Substituted pyridinones as MGAT2 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-05-22 | — | — | US | disclosed |
| US-20170114054-A1 | SUBSTITUTED PYRIDINONES AS MGAT2 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170114054-A1 | SUBSTITUTED PYRIDINONES AS MGAT2 INHIBITORS | PLAAT2, ACAT2, MGAT2 | ABCG2 264/4885MAOB 233/4885MAOA 334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.